From what I read regarding the molecule, It can only be used by Anavex in this Rett research
study so no marketing, however the regulations give latitude for off label usages while
doing this research
From a very liberal reading they could study it's off label use for Alzheimer's for a small group of people.
Perhaps I can share with you my "Welcome to my Ignore List" policy.
My message board experience has been much better for me ever since.
Much faster read.
If the use foul language.. they make it.
If they are mindless bashers ... they make it.
If they are boarder line then I will scroll back a few posts and maybe they will make it.
Woodford will not be happy with a 1 for 10 reverse split. All LP need to do is to announce
the three partners for the Direct trial.
Recommendation:...15 mg per kg for 2 weeks on (5) Phase 1 patients... look for soothing effect.
.........if apparent then increase to 20 then 25 mg. for remediation.
Reason: Non toxic to 50 mg.
Why watch them twitch?
To delay is bull s....
Sentiment: Strong Buy
But remember that your good intentions were thwarted by the organized crime syndicates.
bankers vs banker:broker Carter Glass Act
Uptick rule: 1938 SEC findings. There is needed an Uptick Rule to prevent..
................................................... unwanted selling thus preventing extortion.
The uptick as defined has changed over time..
When first implemented in 1938 it was the last trade plus 3/4 point..
Over the years, the quantity of the uptick has changed as well as the uptick location.
Bottom line: you need an uptick rule that prevents cascade selling.
Thus preventing unwanted selling thus preventing extortion.
The way it is now you can degrade the price 10% a day by fiat force major.
Same extortion but just takes longer.
A just uptick rule would be on the prior day"s close.
Only longs could drive the price down below prior day's close.
Result: higher average price with smaller volatility. Company's stability increased due
to it's currency (stock) being protected as any currency would be.
Sentiment: Strong Buy
another 1000 at .85....
21st century cures act nears senate vote.
3 partners in negotiations with nwbo for phase 3 tests providing much money.
Linda Lui's long tail survivor story.
German and UK approvals
FDA moonshot break thru status.
Supreme Court permission to sue naked shorts in State Court.
Potential for a new and exciting abstract in 3 1/2 hours.
gl to all longs.
Sentiment: Strong Buy
Could this be applied to the cartels that are shorting the gold and silver markets with paper ?
If so then quite bullish for the metals..
For those unable to participate in the conference call, a replay will be available for two weeks beginning on May 16, 2016 through May 30, 2016. To access the replay, the U.S. dial-in number is (877) 660-6853 and the non-U.S. dial-in number is +1 (201) 612-7415. The replay conference ID is 13637632.
"Symposium - Receptor Chemistry Reality and Vision"...
"International Medicinal Chemistry Symposium on Receptor Chemistry"
The most fundamental facets of Chemistry are:
Reagents, Reactions and Results,
How can he talk about the first two without talking about the third?
He should report the Cogstate data, with or without PK/PD data ASAP.
From what I have read, the PKPD data would increase in importance along with drug toxicity.
In Chemotherapy for example. How much to give to kill the cancer before killing the patient.
Seeing as how no safety issues have been raised, the Cogstate data is what counts.
And we have had that for months.
Looking back at the past 12 quarters revenue numbers... Not bad at all..
I was hoping for some of that 50 million of potential business to have walked in the door.
Seems like Apr-Jun and Jul-Sep are the quarters that have had the most revenue in the past.
Hope for a good CC Monday..
With a grain of salt...
PK/PD (Pharmacokinetic/Pharmacodynamic) modeling (alternatively abbreviated as PKPD or PK-PD modeling) is a technique that combines the two classical pharmacologic disciplines of pharmacokinetics and pharmacodynamics It integrates a pharmacokinetic and a pharmacodynamic model component into one set of mathematical expressions that allows the description of the time course of effect intensity in response to administration of a drug dose.
There are a variety of PK/PD modeling approaches, but there are only five major classes:
Direct link PK/PD models
Indirect link PK/PD models
Indirect response PK/PD models
Cell Lifespan models
Complex response models
From what I can gather, the PK/PD modeling is a nice post action report, but has little to do with the patient's overall response to the A2-73 therapy.
Seeing as how an individual persons response to any drug will vary greatly, the gross choice is to adjust the amount given to obtain effectiveness without causing illness.
Week five established that dosage range and safety. The anecdotal evidence of benefit is overwhelming.
Keeping the 26 week test scores hidden because of dose modeling is holding the stock pricing back.
They should be watching those multiple 100 share trades that walk the price down..
That is where the price manipulation is at.
Would not be possible with an uptick rule based on the prior day's close..
If an abstract was sent in and it contained no new data then disappointment would prevail.
If an abstract was sent in and it contained new data then company would be accused of insider information release.. Not being publicly released..
If no abstract then a Press Release could be done Monday and thus fair information release as
well as being able to be talked about at symposium.
just a wag
All data is known to company and to their market makers or suitors.
If not directly then by inference of anecdotal observations.
It is a question of authentication.
With Newlink Genetics they were unloading stock knowing bad news was expected.
With Anavex they are buying stock knowing that good news is expected